IP Library › Granted Patent US 9,260,528
Granted Patent B2
US 9,260,528 · App. 14/735,062 · Granted Feb 16, 2016

DAC HYP compositions and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,260,528
App. No.
14/735,062
Granted
Feb 16, 2016
Kind
B2
Abstract

The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.

Claims (8)

1. A mammalian cell stably transfected with vector pHAT.IgG1.rg.dE.

2. The cell of claim 1 , wherein the cell is a murine myeloma cell.

3. The cell of claim 2 , wherein the cell is an NS0 cell.

4. A method of producing an anti-CD25 monoclonal antibody, comprising culturing a cell of claim 1 , thereby producing an anti-CD25 antibody.

5. The method of claim 4 , wherein the cell is cultured in the absence of serum and cholesterol.

6. The method of claim 5 , wherein the cell is cultured in the absence of animal-derived components.

7. The method of claim 4 , wherein the cell is cultured at a pH of approximately 7.0.

8. The method of claim 4 , wherein the cell is cultured in a basal and/or feed medium containing 10-35 g/L glucose.